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Abstract
Introduction AIB1, located at 20q12, is a member of the steroid
hormone coactivator family. It contains a glutamine repeat
(CAG/CAA) polymorphism at its carboxyl-terminal region that
may alter the transcriptional activation of the receptor and affect
susceptibility to breast cancer through altered sensitivity to
hormones.
Methods We evaluated this repeat polymorphism in the context
of early-onset disease by conducting a case-control study of
432 Australian women diagnosed with breast cancer before the
age of 40 years and 393 population-based control individuals
who were frequency matched for age. Genotyping was
performed using a scanning laser fluorescence imager.
Results There were no differences in genotype frequencies
between cases and control individuals, or between cases
categorized by family history or by BRCA1  and  BRCA2
germline mutation status. There was no evidence that the
presence of one or two alleles of 26 glutamine repeats or fewer
was associated with breast cancer (odds ratio = 1.03, 95%
confidence interval = 0.73–1.44), or that women with alleles
greater than 29 repeats were at increased risk of breast cancer.
Exclusion of women who carried a BRCA1 or BRCA2 mutation
(24 cases) and non-Caucasian women (44 cases) did not alter
the risk estimates or inferences. We present raw data, including
that on mutation carriers, to allow pooling with other studies.
Conclusion There was no evidence that risk of breast cancer
depends on AIB1  CAG/CAA polymorphism status, even if
affected women carry a mutation in BRCA1 or BRCA2.
Introduction
Steroid hormones regulate the expression of proteins that are
involved in breast cell proliferation and development, and
coactivators that interact with steroid hormone receptors to
modulate transcriptional activation have recently been
described [1]. AIB1, located at 20q12, is a member of the
steroid hormone coactivator family that interacts with oestro-
gen receptor-α, resulting in enhancement of oestrogen-
dependent transcription [2]. AIB1 is moderately expressed in
the normal mammary epithelium and is required for female
reproductive function and mammary gland development [3]. It
is overexpressed in 64% of breast tumours, and the 20q12
region has been shown to be amplified in 5–10% of breast
cancers and 7% of ovarian cancers [2,4].
AIB1 contains a glutamine repeat (CAG/CAA) polymorphism
at its carboxyl-terminal region. Although its functional signifi-
cance is currently unknown, it may alter the transcriptional acti-
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vation of the receptor (as is the case for the androgen receptor
CAG repeat polymorphism), and hence it may affect breast
cancer susceptibility through altered sensitivity to hormones
[5]. We evaluated this repeat polymorphism within the context
of early-onset disease by conducting a case-control study of
Australian women diagnosed with breast cancer before the
age of 40 years and population-based control individauls [6,7].
Materials and methods
Participants
The Australian Breast Cancer Family Study is a population-
based, case-control family study conducted in Melbourne and
Sydney [6,8]. For this study, cases were women aged under
40 years at diagnosis of a first primary invasive breast cancer
between 1992 and 1995, and were identified through the Vic-
toria and New South Wales cancer registries. Controls were
women without breast cancer selected via the electoral rolls
(registration is compulsory) between 1993 and 1999 and
were frequency matched for age. Cases and controls were
administered the same questionnaire on risk factors, blood
samples were collected from them at the time of interview, and
a detailed family history was recorded for all first-degree and
second-degree relatives, with verification sought for all reports
of family cancers. To date 25 of these cases have been found
to carry a deleterious germline mutation in BRCA1 and 11 in
BRCA2 [9]. Written informed consent was obtained from all
participants, and approval of the protocol was obtained from
the relevant ethics committees.
Genotype analysis
PCR amplifications were performed with a fluorescent labelled
forward primer (5'-GACAACAGAGGGTGGCTAT-3') and an
unlabelled reverse primer (5'-AGGAGCTTGTGGCATTGTG-
3'). All PCRs were performed in 10 µl volumes containing 10–
50 ng genomic DNA, 200 nmol/l dNTPs (Promega, Annan-
dale, New South Wales, Australia), 25 ng of each primer, 1 ×
ReddyMix buffer (Abgene, Epsom, Surrey, UK) and 0.2 units
of Thermoprime Plus DNA Polymerase (Abgene). PCR ampli-
fication cycle conditions involved an initial denaturation step at
94°C for 5 min, 40 cycles of denaturation at 94°C for 15 s,
annealing at 55°C for 30 s, and extension at 72°C for 45 s.
This was followed by a further extension step at 72°C for 7
min. The alleles were then separated on sequencing gels and
analyzed using a scanning laser fluorescence imager (Bio-Rad
FX Molecular Imager; Bio-Rad, Hercules, CA, USA). DNA was
available for 410 (88%) out of 466 cases and for 441 (74%)
out of 600 controls, and AIBI genotyping was successful for
all but 17 (4%) cases and 9 (2%) controls.
Statistical analysis
Allele frequencies and genotypes were compared using Pear-
son's χ2 test. Odds ratios (ORs) and 95% confidence intervals
(CIs) were calculated using unconditional logistic regression,
adjusting for reference age, study centre, country of birth, edu-
cation level, marital status, number of live births, height, current
oral contraceptive use status and reported first-degree family
history. Routine model diagnostics procedures and goodness-
of-fit were performed to check the adequacy of the logistic
regression models. All tests were performed using Stata ver-
sion 8.0 (Stata Corporation, College Station, TX, USA). Power
calculations were performed using StatCalc module of Epi Info
version 6 (Centers for Disease Control and Prevention [CDC],
Atlanta, GA, USA). All statistical tests were two-sided.
Results
For controls the allele frequencies for 26, 27, 28, 29, 30 and
31 repeats were 0.12, 0.002, 0.36, 0.50, 0.005 and 0.002,
respectively. For cases they were 0.13, 0.001, 0.35, 0.51,
0.004 and 0, respectively. Table 1 shows that there was no dif-
ference overall between breast cancer cases and controls in
allele frequencies (P = 0.7) or genotype frequencies defined
by the number of repeats (P = 0.3). There were no differences
in the genotype distribution of cases by family history (P =
0.1).
Table 2 shows the estimates of breast cancer risk; we chose
a cutoff of 26 repeats or fewer because that had been used in
a previous study [1]. There was no evidence that women with
one or two alleles had increased risk of breast cancer (OR =
1.03, 95% CI = 0.73–1.44) or that women with alleles of
greater than 29 repeats were at increased risk. Exclusion of
women who carried a BRCA1 or BRCA2 mutation (24 cases)
and non-Caucasian women (44 cases) did not alter risk esti-
mates or inferences. For example, the OR for the association
with one or two alleles of 26 repeats or fewer became 1.09
(95% CI = 0.76–1.56).
Discussion
In the present study of Australian women the allele frequencies
and genotype distributions for the AIB1  glutamine repeat
(CAG/CAA) polymorphism were similar to those reported in
previous studies [1,7]. We found no evidence that the risk of
early-onset breast cancer depended on AIB1 genotype. We
have presented the raw data, including that on mutation carri-
ers, to allow pooling with other studies.
The only other study of breast cancer risk and this polymor-
phism in noncarriers of a BRCA1 or BRCA2 mutation was
conducted in women aged 43–69 years [1]; it found no asso-
ciation. Those investigators found a weak suggestion that pre-
menopausal women who carried two short AIB1 repeats were
at decreased risk, but we did not find any support for this in
women under the age of 40 years.
Evidence for an increased risk in women with longer repeat
lengths has been reported in BRCA1 and BRCA2 mutation
carriers [3]. There was no indication from our data that muta-
tion carriers, irrespective of the gene, were at increased risk if
they carried longer repeat lengths, but because of the small
numbers included we had little power to address this issue.Available online http://breast-cancer-research.com/content/7/3/R353
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Conclusion
We found no evidence that risk of breast cancer depends on
AIB1 CAG/CAA polymorphism status, even if affected women
carry a mutation in BRCA1 or BRCA2.
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